Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Terminas
- 2027-02-17
- Atidaryta
- 2026-10-29
- Biudžetas
- 341 600 000 €
- Tipas
- grant
Aprašymas
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope:Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The capacity to produce antibodies that can target new variants and rapidly increase production would serve as an essential preparedness strategy against future health threats, whether from infectious disease epidemics or pandemics.This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation
Tinkamumas (iš šaltinio)
General conditions1. Admissibility Conditions, proposal page limit and layoutAdmissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.2. Eligible CountriesEligible countries are described in Annex B of the Work Programme General Annexes.A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.3. Other Eligibility ConditionsIn recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).Other eligibility conditions are described in Annex B of the Work Programme General Annexes.4. Financial and operational capacity and exclusionFinancial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.5a. Evaluation and award: Award criteria, scoring and thresholdsTo ensure a balanced project portfolio covering the Flaviviruses targeted in this topic[[Flavivirus i to vi, as given in the scope of this topic.]], grants will be awarded (within available budget) to proposals not only in order of ranking but at least also to those proposals that are the highest ranked within different Flaviviruses targeted, provided that the proposals attain all thresholds.Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.5b. Evaluation and award: Submission and evaluation processesThe thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.5c. Evaluation and award: Indicative timeline for evaluation and grant agreementIndicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.6. Legal and financial set-up of the grantsThe granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.Specific conditions Specific conditions are described in the specific topic of the Work Programme. Application and evaluation forms and additional documents: Application and evaluation form templ
Ar šis kvietimas tinka jūsų organizacijai?
Nariams — automatinis tinkamumo vertinimas pagal jūsų profilį, raktažodžių paieška, filtrai, stebėjimo sąrašas ir pranešimai apie naujus panašius kvietimus.